Genmab — Oktober 2016
-
Jeg kan desværre heller ikke se at JJ regnskab kan skubbe væsentlig til kursen i opadgående retning, men til gengæld noget af et fald hvis det ikke indfrier forventninger. Synes Genmab er inde i en tung horisontal bevægelse og hver gang der kommer positivt virker det altid til i forvejen at være priset ind i kursen - gad vide om ikke også det gælder godkendelse til 2. linje!!! Vi får 1-2% stigning og så handles den stille og roligt ned i den efterfølgende uge - gad vide hvad der skal til?
-
yup
-
caruso er på CNBC om lidt
-
other oncology stiger 36% i Q3
-
-
Strong growth in new products include IMBRUVICA
(ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer; DARZALEX -
Worldwide operational results, excluding the net impact of acquisitions, divestitures and hepatitis C sales, were driven by new products and the strength of core products. Strong growth in new products include IMBRUVICA
(ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer; DARZALEX (daratumumab), for the treatment of patients with multiple myeloma; and XARELTO (rivaroxaban), an oral anticoagulant. -
samlet salg omkring $400 mio for 9mdr
?? Er det ikke deromrking vi er?? -
enig
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind